Chinese police reveal more on GSK China's suspected violations
The Chinese police have recently revealed more details about suspected economic violations by UK pharma giant GlaxoSmithKline’s (LSE: GSK) China subsidiary, which has been under investigation since early July for suspected bribery and tax-related violations (The Pharma Letters passim), actions which reportedly have pushed up drug prices in the country, reports the state news agency Xinhua.
The Chinese bribery and corruption allegations have extended to several other multinational drugmakers, including Sanofi, AstraZeneca, Novo Nordisk, Lundbeck and Eli Lilly.
According to the latest report, more individuals involved in the case have admitted some facts of the suspected transgressions. As the investigation is moving on, it is becoming clear that it is organized by GSK China rather than drug salespeople's individual behavior.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze